
-
Cardiff Oncology, Inc. NasdaqCM:CRDF Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated ongoing or planned trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab or SoC FOLFOX and bevacizumab for the first-line treatment of patients with RAS-mutated mCRC; TROV-054, a Phase 1b/2 open-label multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab for the second-line treatment of patients with KRAS-mutated mCRC; and CRDF-001, a Phase 2 open-label multi-center clinical trial of onvansertib in combination with nanoliposomal irinotecan leucovorin, and fluorouracil for second line treatment of patients with mPDAC. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Location: 11055 Flintkote Avenue, San Diego, CA, 92121, United States | Website: https://www.cardiffoncology.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
143.7M
Cash
79.89M
Avg Qtr Burn
-10.69M
Short % of Float
29.30%
Insider Ownership
5.64%
Institutional Own.
45.30%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Onvansertib (monotherapy) Details Cancer, Small cell lung cancer | Phase 2 Data readout | |
Onvansertib + SOC (FOLFIRI + bevacizumab or FOLFOX + bevacizumab) Details Metastatic colorectal cancer Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 2 Data readout | |
Onvansertib + Zytiga (abiraterone) Details Prostate cancer, Cancer, Castration-resistant prostate cancer | Phase 2 Update | |
Onvansertib + nanoliposomal irinotecan (Onyvide®) (PLK1) Details Cancer, Pancreatic cancer, Solid tumor/s | Phase 2 Update | |
Onvansertib + Paclitaxel Details Cancer, Triple-negative breast cancer | Phase 1/2 Update | |
Onvansertib + Second-Line Standard-of-Care (PLK1) Details Colorectal cancer , Cancer | Failed Discontinued | |
Onvansertib + decitabine Details Cancer, Acute myeloid leukemia | Failed Discontinued |